Faucette Azure N, Pawlitz Michael D, Pei Bo, Yao Fayi, Chen Kang
a Department of Obstetrics and Gynecology ; Wayne State University ; Detroit , MI USA.
b Perinatology Research Branch; Eunice Kennedy Shriver National Institute of Child Health and Human Development ; National Institutes of Health ; Detroit , MI USA.
Hum Vaccin Immunother. 2015;11(11):2549-55. doi: 10.1080/21645515.2015.1070984. Epub 2015 Sep 14.
Children in early infancy do not mount effective antibody responses to many vaccines against commons infectious pathogens, which results in a window of increased susceptibility or severity infections. In addition, vaccine-preventable infections are among the leading causes of morbidity in pregnant women. Immunization during pregnancy can generate maternal immune protection as well as elicit the production and transfer of antibodies cross the placenta and via breastfeeding to provide early infant protection. Several successful vaccines are now recommended to all pregnant women worldwide. However, significant gaps exist in our understanding of the efficacy and safety of other vaccines and in women with conditions associated with increased susceptible to high-risk pregnancies. Public acceptance of maternal immunization remained to be improved. Broader success of maternal immunization will rely on the integration of advances in basic science in vaccine design and evaluation and carefully planned clinical trials that are inclusive to pregnant women.
婴儿早期的儿童对许多针对常见传染性病原体的疫苗无法产生有效的抗体反应,这导致了易感性增加或感染严重程度上升的窗口期。此外,疫苗可预防的感染是孕妇发病的主要原因之一。孕期免疫接种可产生母体免疫保护,还能引发抗体的产生,并通过胎盘和母乳喂养进行转移,从而为婴儿提供早期保护。目前,全球已向所有孕妇推荐了几种成功的疫苗。然而,我们对其他疫苗的有效性和安全性以及对与高危妊娠易感性增加相关疾病的女性的了解仍存在重大差距。公众对母体免疫接种的接受度仍有待提高。母体免疫接种的更广泛成功将依赖于基础科学在疫苗设计和评估方面的进展与精心规划的、涵盖孕妇的临床试验的整合。